Research Analysts’ Recent Ratings Changes for Teradyne (TER)

Teradyne (NASDAQ: TER) has recently received a number of price target changes and ratings updates:

• 8/6/2026 – Teradyne was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 7/30/2026 – Teradyne had its price target raised by Morgan Stanley from $387.00 to $397.00. They now have an “equal weight” rating on the stock.
• 7/30/2026 – Teradyne was given a new $420.00 price target by Robert W. Baird.
• 7/30/2026 – Teradyne had its “outperform” rating reaffirmed by Evercore Inc. They now have a $420.00 price target on the stock.
• 7/30/2026 – Teradyne had its price target raised by Morgan Stanley from $387.00 to $397.00. They now have an “equal weight” rating on the stock.
• 7/29/2026 – Teradyne had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $550.00 price target on the stock.
• 7/28/2026 – Teradyne had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $465.00 price target on the stock.
• 7/20/2026 – Teradyne was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 7/20/2026 – Teradyne had its price target raised by UBS Group AG from $440.00 to $500.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Teradyne had its price target raised by The Goldman Sachs Group, Inc. from $350.00 to $465.00. They now have a “buy” rating on the stock.
• 6/30/2026 – Teradyne had its price target raised by Susquehanna from $415.00 to $550.00. They now have a “positive” rating on the stock.
• 6/29/2026 – Teradyne had its price target raised by Cantor Fitzgerald from $400.00 to $550.00. They now have an “overweight” rating on the stock.
• 6/23/2026 – Teradyne had its price target raised by Bank of America Corporation from $365.00 to $525.00. They now have a “buy” rating on the stock.
• 6/23/2026 – Teradyne had its price target raised by Robert W. Baird from $350.00 to $446.00. They now have an “outperform” rating on the stock.

Insider Buying and Selling at Teradyne

In other Teradyne news, CEO Gregory Stephen Smith sold 4,000 shares of Teradyne stock in a transaction on Monday, June 15th. The shares were sold at an average price of $423.03, for a total value of $1,692,120.00. Following the completion of the transaction, the chief executive officer owned 120,470 shares of the company’s stock, valued at approximately $50,962,424.10. The trade was a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon John Poulin sold 1,008 shares of the company’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $345.37, for a total transaction of $348,132.96. Following the completion of the transaction, the insider owned 15,066 shares of the company’s stock, valued at approximately $5,203,344.42. This trade represents a 6.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 5,664 shares of company stock valued at $2,273,133. Company insiders own 0.19% of the company’s stock.

Teradyne, Inc is a global supplier of automatic test equipment and related services principally used to test semiconductors, wireless products and complex electronic systems. Founded in 1960, the company is headquartered in North Reading, Massachusetts, and has a long history of developing capital equipment and software that help semiconductor manufacturers, electronics OEMs and contract manufacturers validate product performance and reliability during design and production.

The company’s product portfolio centers on automatic test equipment (ATE) and system-level test solutions that address chip- and board-level validation, burn-in and reliability screening.